News & Updates

The overexpression of the hepatocellular carcinoma upregulated EZH2-associated family of long noncoding RNA appears to be a risk factor for worse clinicopathologic characteristics and outcomes for cancer patients, reports a recent meta-analysis.

First-line treatment with tislelizumab + chemotherapy significantly improves overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy alone, according to an interim analysis of the RATIONALE-306* trial presented at ESMO GI 2022.

Women who use taxane chemotherapy agents are likely to experience epiphora, cystoid macular edema, and optic neuropathy, as reported in a retrospective cohort study.

Patients with oesophageal squamous cell carcinoma (ESCC) see better survival and safety outcomes after treatment with neoadjuvant chemoradiation therapy (NCRT) as compared with neoadjuvant chemotherapy (NCT) alone, according to a recent meta-analysis.

The incidence of myocarditis and myocardial damage is higher than expected in cancer patients receiving immune checkpoint inhibitor (ICI) treatment, reports a recent real-world study.

A history of abnormalities found during ultrasonography appears to aggravate the diagnosis of cholangiocarcinoma, particularly among those with dilated bile ducts and liver mass, reports a recent Thailand study.